To identify and summarize the key characteristics, strengths, and weaknesses of available patient-reported outcome (PRO) measures assessing treatment satisfaction and health-related quality of life (HRQOL) related to anticoagulation therapy in patients with atrial fibrillation, including evaluating how well the measures meet current regulatory guidance requirements in Europe and the United States.
